Search Results

You are looking at 221 - 230 of 866 items for :

  • Refine by Access: All x
Clear All
Full access

New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields

added. With a couple more questions, the health care provider can quickly gauge the challenges for quitting and the risk of relapse. Then the algorithm provides guidance for evaluating Figure 1 Pharmacotherapy options for smoking cessation

Full access

New Treatment Options for the Management of Multiple Myeloma

Shaji K. Kumar

approaching MM is to make sure the diagnosis is correct. Identifying the time point for therapy is critical. Despite effective treatment, most patients will eventually relapse. Hopefully we can offer patients an extended, treatment-free interval,” Dr. Kumar

Full access

Non-Hodgkin's Lymphomas

Andrew D. Zelenetz, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis E. Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nashitha Reddy, Lubomir Sokol, Lode J. Swinnen, Christina Tsien, Julie M. Vose, William G. Wierda, Joachim Yahalom, and Nadeem Zafar

essentially eliminated because residual masses were defined as a partial or complete response based on the result of a PET scan. Using the revised system, response is categorized as complete response, partial response, stable disease, and relapsed disease or

Full access

Rational Use of Cytotoxic Chemotherapy for Recurrent Ovarian Cancer

Joyce Liu and Ursula Matulonis

of survival following second-line chemotherapy in small cell lung cancer and ovarian patients . Int J Oncol 1999 ; 15 : 1233 – 1238 . 7. Medical Research Council . OV05: A randomized trial in relapsed ovarian cancer: early treatment

Full access

Infectious Complications Associated With Immunomodulating Monoclonal Antibodies Used in the Treatment of Hematologic Malignancy

Sophia Koo and Lindsey R. Baden

. 17. Archimbaud C Bailly JL Chambon M . Molecular evidence of persistent echovirus 13 meningoencephalitis in a patient with relapsed lymphoma after an outbreak of meningitis in 2000 . J Clin Microbiol 2003 ; 41 : 4605 – 4610 . 18

Full access

Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia

Martin Tallman

core binding factor and possibly intermediate risk who are treatment-naïve (and may also be used in patients with relapsed/refractory AML); enasidenib (IDH2 inhibitor) for relapsed/refractory AML with IDH2 mutations; CPX-351 (new 5:1 liposomal

Full access

Idelalisib and Rituximab in 17p Deletion–Positive Splenic Marginal Zone Lymphoma

Aby Z. Philip

, and idelalisib have been studied in indolent lymphoma, and these trials have included a subset of patients with MZL. Vorinostat demonstrated an ORR of 22% as a single agent 14 in the MZL subgroup of relapsed/refractory (R/R) indolent NHL. Ibrutinib

Full access

NCCN Guidelines Update: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Deborah M. Stephens

observed following relapse after this regimen, suggesting that time-limited therapy may limit the number of patients who become resistant to the drug. 3 Among the cons, however, Dr. Stephens noted the toxicity observed in patients aged >65 years

Full access

Adult Acute Lymphocytic Leukemia: Strategies for Selection of Consolidation Therapy

Presented by: Aaron C. Logan

-Frankfurt-Münster; Hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone. According to Dr. Logan, poor prognosis remains one of the major challenges for adults with relapsed/refractory ALL, with survival rates <50%. 4 , 5 This concern has led to

Full access

Updates in the Management of Newly Diagnosed Acute Myeloid Leukemia

Presented by: Alice S. Mims

and cytarabine (CPX-351), which is now approved for secondary or therapy-related AML. After further analysis in both the up-front and relapsed/refractory (R/R) settings, gemtuzumab ozogamicin (GO) came back onto the scene. In 2018, the field saw the